Ursprung des Netzwerks ersten Grades von Helle Busck Fensvig
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Curalogic AS
Curalogic AS Pharmaceuticals: MajorHealth Technology The Group's principal activities is the development of pharmaceuticals for the treatment of allergy.
1
| Extinct | Pharmaceuticals: Major | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Helle Busck Fensvig
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
CORVUS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ALIGOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Yale University | College/University | Doctorate Degree | |
Viewpoint Therapeutics, Inc.
Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Viewpoint Therapeutics, Inc. operates as a biotechnology company. It prevents and treats cataracts and presbyopia, and protein misfolding. The company was founded by Leah Makley in July of 2014 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
BOLT BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman | |
Outpost Medicine, Inc.
Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | Pharmaceuticals: Major | Director/Board Member | |
SPRUCE BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal | |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Thesan Pharmaceuticals, Inc.
Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Pharmaceuticals: Major | Director/Board Member | |
NTG NORDIC TRANSPORT GROUP A/S | Trucking | Corporate Officer/Principal | |
ALLAKOS INC. | Pharmaceuticals: Major | Chairman | |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Investment Managers | Private Equity Investor | |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
Cardeas Pharma Corp.
Cardeas Pharma Corp. Pharmaceuticals: MajorHealth Technology Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member | |
Danmarks Farmaceutiske Universitet | College/University | Doctorate Degree | |
7TM A/S
7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Founder | |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member |
Statistik
International
Vereinigte Staaten | 15 |
Dänemark | 9 |
Vereinigtes Königreich | 2 |
Kanada | 2 |
Sektoral
Health Technology | 18 |
Finance | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Transportation | 2 |
Operativ
Director/Board Member | 17 |
Independent Dir/Board Member | 3 |
Corporate Officer/Principal | 3 |
Doctorate Degree | 2 |
Chairman | 2 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Peter Moldt | 25 |
- Börse
- Insiders
- Helle Busck Fensvig
- Unternehmensverbindungen